Skip to main content
Figure 6 | Radiation Oncology

Figure 6

From: Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer

Figure 6

Tumor growth delay curves for PC3 xenografts treated with the combination of sunitinib and radiation. Tumors were generated by inoculation of PC3 cells into legs of nude mice and treatments initiated when tumors grew to 7 mm. Panel A: untreated control, vehicle only for 5 days, sunitinib (1.2 mg/mouse) only for 5 days, local tumor radiation only (3 Gy daily for 5 days), sunitinib for 5 days 1 h before each radiation dose, sunitinib for 5 days beginning 1 day after completion of 5 radiation doses. Panel B: untreated control, vehicle only for 5 days, sunitinib (1.3 mg/mouse) only for 5 days, local tumor radiation only (1 Gy daily for 5 days), sunitinib for 5 days 1 h before each of 5 radiation doses, sunitinib for 5 days beginning 1 day after completion of 5 radiation doses. Each data point represents average tumor diameter for 6–8 mice; bars, SE.

Back to article page